• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LifeVantage Appointing Terrence Moorehead as Chief Executive Officer

    4/16/26 5:15:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email

    SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) ("LifeVantage" or the "Company"), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Terrence Moorehead as the Company's new President and Chief Executive Officer and as a member of the Board of Directors (the "Board"), effective August 5, 2026. Mr. Moorehead is expected to commence employment with LifeVantage following the completion of his contractual commitments with his prior employer.

    Mr. Moorehead brings more than 25 years of leadership experience revitalizing brands, accelerating customer growth, and delivering sustained financial performance in the direct selling and consumer products industries. He previously served as President and Chief Executive Officer of Nature's Sunshine Products, Inc. from 2018 through 2025 where he led the company through a multi-year transformation that redefined the business and increased revenue 45% and EBITDA 190%. From 2015 through 2018, he served as Chief Executive Officer of Carlisle Etcetera LLC. From 2013 through 2015, he served as Chief Executive Officer of Dana Beauty, Inc. From 1991 to 2013, he served in various leadership roles at Avon Products, Inc., including VP, Strategy and Digital, for North America, General Manager of Avon Italy, President of Avon Canada, and Chairman and President of Avon Japan.

    "Terrence has an outstanding track record of driving growth and scaling leading, global health and wellness brands and we are thrilled to welcome him as our next CEO," said Raymond Greer, Chairman of the Board of LifeVantage. "Following a comprehensive search process, the Board unanimously concluded that Terrence's proven ability to lead transformations and his extensive experience in sales, marketing, and finance make him the best choice for the Company and its stockholders, to guide LifeVantage in its next exciting chapter."

    "I'm honored to join LifeVantage at this pivotal moment," said Mr. Moorehead. "The Company's uniquely differentiated science-backed products, passionate consultant community and dedicated employees create a powerful foundation for the future. I see tremendous potential to further leverage the strong brand position and capabilities and am excited to work alongside the Board and our entire team to sharpen our strategy, drive sustainable growth and deliver meaningful value for our stockholders."

    The previously announced retirement of Steve Fife as President, CEO and as a member of the Board is set to take effect on April 30, 2026. In connection with this planned transition, the Board has appointed current director Michael Beindorff as Interim CEO, along with Executive Advisors Kristen Cunningham, Chief Sales Officer, and Carl Aure, Chief Financial Officer, to lead the Company until Mr. Moorehead assumes the role of CEO.

    Mr. Greer continued, "On behalf of the entire Board, I want to thank Steve for his leadership and many contributions to LifeVantage over the past nine years. Steve's vision and dedication were essential in transforming and modernizing our business model, strengthening our financial position, along with expanding our product portfolio and international footprint, ensuring the Company is well positioned for long-term success. We appreciate his commitment to supporting a smooth transition and wish him the very best in his retirement.  

    "Our interim leadership team comprises highly experienced executives committed to our mission and ensuring continuity for our employees, consultants, and customers. Michael's long history with the Company and strategic perspective as a Board member, combined with the leadership team's breadth and depth of experience across the entire enterprise, position them well to steward the business through this transition period."

    About LifeVantage Corporation

    LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics-the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 System™, and the comprehensive gut activator P84, and the activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

    Cautionary Note Regarding Forward Looking Statements

    This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," "may be," and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, the commencement of Mr. Moorehead's employment as the Company's CEO and his service as a director and expectations related to these announcements. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the "SEC"). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

    Investor Relations Contacts:

    Reed Anderson, ICR 

    (646) 277-1260

    [email protected]



    Primary Logo

    Get the next $LFVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cunningham Kristen

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:06 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Neufeld Alissa

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:07 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Aure Carl

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:06 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    SEC Filings

    View All

    Lifevantage Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    4/16/26 5:15:15 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lifevantage Corporation

    EFFECT - Lifevantage Corp (0000849146) (Filer)

    3/23/26 12:15:12 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Lifevantage Corporation

    S-3 - Lifevantage Corp (0000849146) (Filer)

    3/10/26 4:27:58 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dayton Judd bought $152,422 worth of shares (33,197 units at $4.59), increasing direct ownership by 70% to 80,359 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    3/2/26 6:44:28 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $20,651 worth of shares (3,955 units at $5.22), increasing direct ownership by 3% to 135,508 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    2/11/26 4:32:08 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $5,265 worth of shares (805 units at $6.54), increasing direct ownership by 0.62% to 131,553 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    12/17/25 4:23:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LifeVantage Appointing Terrence Moorehead as Chief Executive Officer

    SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) ("LifeVantage" or the "Company"), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Terrence Moorehead as the Company's new President and Chief Executive Officer and as a member of the Board of Directors (the "Board"), effective August 5, 2026. Mr. Moorehead is expected to commence employment with LifeVantage following the completion of his contractual commitments with his prior employer. Mr. Moorehead brings more than 25 years of leadership experience revitalizing brands, accelerating customer gr

    4/16/26 5:15:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Participate in Water Tower Research Insights Conference on Wednesday, April 15, 2026

    SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, Kristen Cunningham, Chief Sales Officer, and Lisa Barnes, Vice President Research & Development and Regulatory, will participate in the upcoming Water Tower Research Insights Conference on Wednesday, April 15, 2026. The webcast of the presentation will begin at approximately 12:30 p.m. Eastern Time on Wednesday, April 15, 2026. The event is open access for all investors and interested parties can register direc

    4/9/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Participate in the Sidoti Small Cap Conference

    SALT LAKE CITY, March 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the Sidoti Small Cap Conference, to be held March 18-19, 2026. Mr. Fife and Mr. Aure will meet virtually with investors and present at approximately 4:00 p.m. Eastern Time on Thursday, March 19, 2026. A live webcast of their presentation will be accessible on the News & Events section of the Company's Investor Relations website at https://lifevantage.gcs

    3/16/26 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Appointing Terrence Moorehead as Chief Executive Officer

    SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) ("LifeVantage" or the "Company"), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Terrence Moorehead as the Company's new President and Chief Executive Officer and as a member of the Board of Directors (the "Board"), effective August 5, 2026. Mr. Moorehead is expected to commence employment with LifeVantage following the completion of his contractual commitments with his prior employer. Mr. Moorehead brings more than 25 years of leadership experience revitalizing brands, accelerating customer gr

    4/16/26 5:15:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation

    SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the addition of Mike Edwards as Chief Technology Officer. Edwards brings more than 25 years of experience as an accomplished senior executive specializing in technology leadership and enterprise transformation. "Mike is a strategic leader with a strong track record of translating technological innovation into measurable business impact and we are delighted to have him join the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "His expertise in eCo

    1/7/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:29:36 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:27:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Financials

    Live finance-specific insights

    View All

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid March 16, 2026 to all stockholders of record at the close of business on March 2, 2026. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products w

    2/4/26 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025. Second Quarter Fiscal 2026 Summary*: Revenue was $48.9 million, a decrease of 27.8% from the prior year period. Revenue was up 2.9% sequentially from the first quarter.Revenue in the Americas decreased 32.6%, and revenue in Asia/Pacific & Europe decreased 2.1%.Net income per diluted share was $0.02, versus $0.19 per diluted share a year ago;Adjusted earnings per diluted share was $0.15, compared

    2/4/26 4:04:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026

    SALT LAKE CITY, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its second quarter ended December 31, 2025, after the stock market closes on Wednesday, February 4, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hour

    1/21/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care